Iben Spanggaard
Impact in
- Biotechnology top 10%
- Microbial Inactivation Methods
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 22
- HER2/EGFR in Cancer Research 5
- Colorectal Cancer Treatments and Studies 4
-
- Fibroblast Growth Factor Research 5
- Viral Infectious Diseases and Gene Expression in Insects 4
- Co-authors
- Janne Bigaard (1 shared paper)Birthe Lykke Thomsen (1 shared paper)Anne Tjønneland (1 shared paper)Kim Overvad (1 shared paper)Kristoffer Staal Rohrberg (19 shared papers)Ulrik Lassen (15 shared papers)Julie Gehl (7 shared papers)Lise Barlebo Ahlborn (4 shared papers)
- Journals
- Annals of Oncology (8 papers)Journal of Clinical Oncology (6 papers)Acta Oncologica (3 papers)BMC Cancer (2 papers)Advanced Healthcare Materials (2 papers)
- Partner nations
- DenmarkUnited StatesFrance
In The Last Decade
Iben Spanggaard
37 papers receiving 550 citations
Iben Spanggaard's Hit Papers
Peers
Comparison fields: 5 of 71
- Biotechnology 78
- Oncology 239
- Cancer Research 124
- Pharmacy 20
- Pulmonary and Respiratory Medicine 118
Countries citing papers authored by Iben Spanggaard
This map shows the geographic impact of Iben Spanggaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iben Spanggaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iben Spanggaard more than expected).
Fields of papers citing papers by Iben Spanggaard
This network shows the impact of papers produced by Iben Spanggaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iben Spanggaard. The network helps show where Iben Spanggaard may publish in the future.
Co-authors
The 25 scholars most cited alongside Iben Spanggaard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 88 | |
| 2 | 2018 | 59 | |
| 3 | 2013 | 53 | |
| 4 | Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study Hit paper breakdown → | 2024 | 43 |
| 5 | 2021 | 26 | |
| 6 | 2024 | 24 | |
| 7 | 2021 | 24 | |
| 8 | 2023 | 19 | |
| 9 | 2022 | 18 | |
| 10 | 2021 | 16 | |
| 11 | 2011 | 16 | |
| 12 | 2024 | 15 | |
| 13 | 2019 | 15 | |
| 14 | 2022 | 14 | |
| 15 | 2022 | 14 | |
| 16 | 2019 | 13 | |
| 17 | 2020 | 13 | |
| 18 | 2020 | 12 | |
| 19 | 2021 | 12 | |
| 20 | 2023 | 11 |
About Iben Spanggaard
Iben Spanggaard is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Surgery, having authored 43 papers that have together received 561 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (13 papers), Lung Cancer Treatments and Mutations (7 papers), Microbial Inactivation Methods (6 papers), HER2/EGFR in Cancer Research (5 papers), Fibroblast Growth Factor Research (5 papers), Gastric Cancer Management and Outcomes (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (4 papers). The work is most often cited by research in Biotechnology (78 citations), Oncology (239 citations), Cancer Research (124 citations), Pharmacy (20 citations) and Pulmonary and Respiratory Medicine (118 citations). Iben Spanggaard has collaborated with scholars based in Denmark, United States and France. Frequent co-authors include Janne Bigaard, Birthe Lykke Thomsen, Anne Tjønneland, Kim Overvad, Kristoffer Staal Rohrberg, Ulrik Lassen, Julie Gehl, Lise Barlebo Ahlborn, Christina W. Yde and Morten Mau‐Sørensen. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Acta Oncologica, BMC Cancer and Advanced Healthcare Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.